Journal article
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board
JCO precision oncology, Vol.1, pp.1-10
01/01/2017
DOI: 10.1200/PO.16.00022
PMCID: PMC7450916
PMID: 32913980
Abstract
Purpose Precision oncology develops and implements evidence-based personalized therapies that are based on specific genetic targets within each tumor. However, a major challenge that remains is the provision of a standardized, up-to-date, and evidenced-based precision medicine initiative across a geographic region.
Materials and Methods We developed a statewide molecular tumor board that integrates academic and community oncology practices. The Precision Medicine Molecular Tumor Board (PMMTB) has three components: a biweekly Web-based teleconference tumor board meeting provided as a free clinical service, an observational research registry, and a monthly journal club to establish and revise evidence-based guidelines for off-label therapies. The PMMTB allows for flexible and rapid implementation of treatment, uniformity in practice, and the ability to track outcomes.
Results We describe the implementation of the PMMTB and its first year of activity. Seventy-seven patient cases were presented, 48 were enrolled in a registry, and 38 had recommendations and clinical follow-up. The 38 subjects had diverse solid tumors (lung, 45%; GI, 21%; breast, 13%; other, 21%). Of these subjects, targeted therapy was recommended for 32 (84%). Clinical trials were identified for 24 subjects (63%), and nontrial targeted medicines for 16 (42%). Nine subjects (28%) received recommended therapy with a response rate of 17% (one of six) and a clinical benefit rate (partial response + stable disease) of 38% (three of eight). Although clinical trials often were identified, patients rarely enrolled.
Conclusion The PMMTB provides a model for a regional molecular tumor board with clinical utility. This work highlights the need for outcome registries and improved access to clinical trials to pragmatically implement precision oncology. Precis Oncol 00. (C) 2017 by American Society of Clinical Oncology
Details
- Title: Subtitle
- Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board
- Creators
- Mark E. Burkard - University of Wisconsin HealthDustin A. Deming - University of Wisconsin HealthBenjamin M. Parsons - University of Wisconsin HealthParaic A. Kenny - University of Wisconsin HealthMarissa R. Schuh - University of Wisconsin HealthTiciana Leal - University of Wisconsin HealthNataliya Uboha - University of Wisconsin HealthJoshua M. Lang - University of Wisconsin HealthMichael A. Thompson - University of Wisconsin HealthRuth Warren - University of Wisconsin HealthJordan Bauman - University of Wisconsin HealthMary S. Mably - University of Wisconsin HealthJennifer Laffin - University of Wisconsin HealthCatherine R. Paschal - University of Wisconsin–MadisonAngela M. Lager - University of Wisconsin HealthKristy Lee - University of Wisconsin HealthKristina A. Matkowskyj - University of Wisconsin HealthDarya G. Buehler - University of Wisconsin HealthWilliam M. Rehrauer - University of Wisconsin HealthJill Kolesar - University of Wisconsin Health
- Resource Type
- Journal article
- Publication Details
- JCO precision oncology, Vol.1, pp.1-10
- DOI
- 10.1200/PO.16.00022
- PMID
- 32913980
- PMCID
- PMC7450916
- NLM abbreviation
- JCO Precis Oncol
- eISSN
- 2473-4284
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 10
- Grant note
- P30 CA014520 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 01/01/2017
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984696549402771
Metrics
7 Record Views